Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LAPATINIB DITOSYLATE Cause Skin hyperpigmentation? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Skin hyperpigmentation have been filed in association with LAPATINIB DITOSYLATE (Lapatinib). This represents 0.1% of all adverse event reports for LAPATINIB DITOSYLATE.

5
Reports of Skin hyperpigmentation with LAPATINIB DITOSYLATE
0.1%
of all LAPATINIB DITOSYLATE reports
0
Deaths
0
Hospitalizations

How Dangerous Is Skin hyperpigmentation From LAPATINIB DITOSYLATE?

Of the 5 reports.

Is Skin hyperpigmentation Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LAPATINIB DITOSYLATE. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does LAPATINIB DITOSYLATE Cause?

Diarrhoea (893) Death (665) Nausea (317) Fatigue (301) Vomiting (259) Rash (249) Drug ineffective (183) Malignant neoplasm progression (183) Off label use (141) Disease progression (137)

What Other Drugs Cause Skin hyperpigmentation?

ADAPALENE (2,811) AVOBENZONE\OCTISALATE\OCTOCRYLENE (2,277) BIMATOPROST (189) AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OXYBENZONE (182) DUPILUMAB (177) MINOCYCLINE (144) LENALIDOMIDE (142) METHOTREXATE (142) CAPECITABINE (136) COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES (120)

Which LAPATINIB DITOSYLATE Alternatives Have Lower Skin hyperpigmentation Risk?

LAPATINIB DITOSYLATE vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN LAPATINIB DITOSYLATE vs LARONIDASE LAPATINIB DITOSYLATE vs LAROTRECTINIB LAPATINIB DITOSYLATE vs LASILIX LAPATINIB DITOSYLATE vs LASIX

Related Pages

LAPATINIB DITOSYLATE Full Profile All Skin hyperpigmentation Reports All Drugs Causing Skin hyperpigmentation LAPATINIB DITOSYLATE Demographics